Immunicon Corp.

Brian J. Geiger , 63, has served as one of our directors since August 2000. Mr. Geiger serves as Chair of our Audit and Compliance Committee and serves on our Compensation Committee and Nominating and Governance Committee. Mr. Geiger served as Executive Vice President and Chief Financial Officer of Ascendia Brands, Inc., a manufacturer, marketer and distributor of health and beauty aid products from May 2004 until July 2006. From 1997 to March 2004, Mr. Geiger served as Executive Vice President and Chief Financial Officer of Claneil Enterprises, Inc., a private equity firm. Mr. Geiger holds a B.A. in Economics from Rutgers University, an M.B.A. in Finance from Seton Hall University, and has been a C.M.A. since 1986.

Prior to joining Canaan, Seth served as CEO and Chairman at CytoTherapeutics (CTII). Before that, he helped start and served as head of R&D for Ortho Biotech, a division of Johnson & Johnson. In that role, he led the development efforts for a portfolio of projects which are still responsible for significant Johnson and Johnson revenues. He began his industrial career at Schering-Plough where he ran clinical trials for the alpha interferon project, and later transferred to Biogen to run that company's pharmaceutical development efforts. His academic career began when he served on the medical and public health faculty at Chapel Hill. Seth is a Clinical Professor of Medicine at Chapel Hill where he teaches and advises the faculty on biotechnology issues. Recently, Seth was included in the 2006 Midas List, a prominent venture capital listing which ranks the best dealmakers in high-tech and life sciences.